Determination of Predictors Associated With HIV/AIDS Patients on ART Using Accelerated Failure Time Model for Interval Censored Survival Data

Swain, Prafulla Kumar; Grover, Gurprit

doi:10.3844/amjbsp.2016.12.19

Cited by 7 publications

(8 citation statements)

References 48 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a higher mortality rate in the first 3–6 months of therapy which was similar to findings in studies conducted in different countries, 1 , 26 , 27 and this might be due to immune reconstitution syndrome associated with the initiation of HAART. The patients who come to health centers may be after developing full-blown AIDS.…”

Section: Discussionsupporting

confidence: 86%

“…2,15,24 This finding was higher as compared to studies done in Axum (8%) and Canada (5%), which may result from a difference in the quality of care provided. 2,25 There was a higher mortality rate in the first 3-6 months of therapy which was similar to findings in studies conducted in different countries, 1,26,27 and this might be due to immune reconstitution syndrome associated with the initiation of HAART. The patients who come to health centers may be after developing full-blown AIDS.…”

Section: Discussionsupporting

confidence: 85%

“…The median age at the time of HAART initiation was ±35.3 (27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42) years. From the total of patients' charts, 199 (26.70%) were within the age group of 28-35 years, 347 (46.51%) were males, and 102 (13.67%) patients were…”

Section: Socio-demographic Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Survival Time and Associated Factors Among Adults Living with HIV After Initiation of HAART in South Gondar, Northwest Ethiopia: A Retrospective Cohort

Deres

Nigussie²,

Chanie³

et al. 2021

JMDH

View full text Add to dashboard Cite

Background Antiretroviral therapy consistently improves the survival of people living with HIV and contributes to preventing the development of new infections. Studies of antiretroviral therapy programs in Africa have shown a high mortality rate during the first 6 months after initiation of HAART in rural health facilities. This study looks at survival time and associated factors among adults with HIV in south Gondar, Northwest Ethiopia. Methods A 5-year retrospective cohort study design was conducted using patient records among 746 adults living with HIV/AIDS. A systematic random sampling technique was used to select respondents after proportional allocation was made for all health facilities included in the study. Epi-info version 7 and STATA 12 were used for data entry and analysis, respectively. Kaplan–Meier survival analysis was used to estimate mean survival time and a life table was used to estimate survival probability after initiation of HAART. Results A total of 746 respondents were followed for a median of 60 months. There were 102 (13.67%) deaths yielding an overall mortality rate of 2.59/1,000-person year observation (95% CI=0.02136–0.031736). Age of respondents >43 years (AHR=2.790; 95% CI=1.495–5.206), bedridden (AHR=9.57; 95% CI=3.87–23.64), past TB treatment (AHR=0.86; 95% CI=0.46–0.609), baseline WHO stage IV (AHR=3.02; 95% CI=1.77–5.18), pneumonia after ART start (AHR=3.6; 95% CI=1.4–9.2), INH prophylaxis (AHR=2.58; 95% CI=1.232–5.188), ambulatory functional status (AHR=5.86; 95% CI=2.67–12.86), and disclosure status (AHR=0.423; 95% CI=0.261–0.685) were significant predictors for survival time after initiation of HAART among adults living with HIV. Conclusion The mortality rate was highly (13.67%) observed in the early phase of antiretroviral treatment. Being ambulatory and bedridden, age of respondents >43 years, past TB treatment, baseline WHO stage IV, pneumonia after HAART, INH prophylaxis, and disclosure status were independent predictors of mortality.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Survival Time and Associated Factors Among Adults Living with HIV After Initiation of HAART in South Gondar, Northwest Ethiopia: A Retrospective Cohort

Deres

Nigussie²,

Chanie³

et al. 2021

JMDH

View full text Add to dashboard Cite

show abstract

“…The BMI of patients with HIV is an important predictor of ART outcome,5–8 including the prediction of the CD4 cells change9 and death 10–12. A negative change in BMI of patients was also found to be an independent predictor of dropout from HIV care 13…”

Section: Introductionmentioning

confidence: 98%

Body mass index variation over time and associated factors among HIV-positive adults on second-line ART in north-west Ethiopia: a retrospective follow-up study

et al. 2019

View full text Add to dashboard Cite

ObjectivesThis study aimed to assess the evolution of body mass index (BMI) of HIV-positive adults on second-line antiretroviral therapy (ART) over time and factors affecting it in north-west Ethiopia.DesignAn institution-based retrospective follow-up study was conducted using data extracted from 1016 patient cards from February 2008 to February 2016.SettingEight referral hospitals from Amhara region, Ethiopia were included.ParticipantsHIV patients who started second-line ART.Outcome measuresChange in BMI since starting second-line ART.ResultsFive hundred and thirty-eight (52.95%) participants were males and the median age of the participants was 33 years (IQR: 28; 39). The median follow-up time was 18 months (IQR: 5.2; 32.2). The average change of BMI showed linear increase over time. The amount of BMI increment or decrement according to each variable was shown as β coefficients. Treatment duration (β=0.013, 95% CI 0.004 to 0.022), isoniazid prophylaxis (β=0.87, 95% CI 0.32 to 1.42), cotrimoxazole prophylaxis (β=0.63, 95% CI 0.08 to 1.19), ambulatory functional status (β=−1.16, 95% CI −1.95 to 1.31), bedridden functional status (β=−1.83, 95% CI −2.47 to 1.21), WHO stage III (β=−0.42, 95% CI −0.65 to 0.20), WHO stage IV (β=−0.62, 95% CI −1.02 to 0.22), CD4 count (β=0.001, 95% CI 0.0008 to 0.0015), and time interaction of variables like tertiary educational status (β=0.02, 95% CI 0.01 to 0.04), ambulatory functional status (β=0.03, 95% CI 0.01 to 0.05) and WHO stages III (β=0.01, 95% CI 0.007 to 0.02) were found to be significant predictors.ConclusionThe BMI of patients has shown linear increment over the treatment time. Factors affecting it have been identified but its effect on cardiovascular disease needs further study.

show abstract

“…(4) The body mass index of HIV patients is an important predictor of antiretroviral outcomes (5)(6)(7) including prediction of CD4 cell changes (8) and death. (9)(10)(11) Negative changes in a patient's BMI are also independent predictors of dropout from HIV care cases. (12) The BMI of HIV patients is influenced by gender, WHO stage (13) , duration of treatment, (14)(15) and CD4 cell count.…”

Section: Introductionmentioning

confidence: 99%

Body mass index increases CD4+ count in HIV/AIDS patients on first-line therapy

et al. 2020

View full text Add to dashboard Cite

Background The body mass index (BMI) may contribute somewhat to drug metabolism, thus affecting the efficacy of antiretroviral therapy (ART). CD4+ counts in people infected with HIV are essential in determining the stage of the disease, initiation of antiretroviral therapy, opportunistic infections and evaluating treatment outcomes. The aim of this study was to determine the association of BMI and clinical stage with CD4+ counts in HIV patients seeking treatment using first-line antiretroviral therapy (ART). Methods An analytic study with a cross-sectional approach was conducted involving 251 HIV/AIDS patients who had received first-line antiretrovirals over six months. BMI, clinical staging according to WHO and CD4 + were collected. Multiple linear regression was used to evaluate the relationship between BMI, clinical stage and CD4+. Results Among the enrolled patients, the median age was 36 years, 135 (55%) of the patients was female, 102 (40.6%) was overweight/obese, 161 (64.1%) was in stage 3 of the disease, and the median CD4+ count was 389 cells/mm3. Multiple linear regression test showed two variables with a significant effect on CD4+ count, namely BMI (B=69.247; 95 % CI : 42.886-95.608) and clinical stage (B=61.590; 28.910-94.270). BMI was the most influencing factor for CD4+ count (β=0.307) compared to clinical stage (β=0.216). Conclusions Body mass index was the most influencing factor for CD4 + counts of HIV/AIDS patients. Regular ART can increase CD4+ counts and maintain the health of HIV/AIDS patients.

show abstract

Determination of Predictors Associated With HIV/AIDS Patients on ART Using Accelerated Failure Time Model for Interval Censored Survival Data

Cited by 7 publications

References 48 publications

Survival Time and Associated Factors Among Adults Living with HIV After Initiation of HAART in South Gondar, Northwest Ethiopia: A Retrospective Cohort

Survival Time and Associated Factors Among Adults Living with HIV After Initiation of HAART in South Gondar, Northwest Ethiopia: A Retrospective Cohort

Body mass index variation over time and associated factors among HIV-positive adults on second-line ART in north-west Ethiopia: a retrospective follow-up study

Body mass index increases CD4+ count in HIV/AIDS patients on first-line therapy

Contact Info

Product

Resources

About